Striatal reward activity and antipsychotic-associated weight change in patients with schizophrenia undergoing initial treatment

JAMA Psychiatry

Volumn 73, Issue 2, 2016, Pages 121-128

  Nielsen, Mette O ^a   Rostrup, Egill ^a   Wulff, Sanne ^a   Glenthøj, Birte ^a   Ebdrup, Bjørn H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; ANTHROPOMETRY; ANTICIPATION; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HOSPITAL PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OBESITY; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PUTAMEN; REWARD; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; ADOLESCENT; ANALOGS AND DERIVATIVES; DRUG EFFECTS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICIPATION, PSYCHOLOGICAL; ANTIPSYCHOTIC AGENTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PUTAMEN; REWARD; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 84957693158     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.2582     Document Type: Article

References (55)

1. Laursen TM,Wahlbeck K, Hällgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013; 8(6): E67133.
2. Kredentser MS, Martens PJ, Chochinov HM, Prior HJ. Cause and rate of death in people with schizophrenia across the lifespan: A population-based study in Manitoba, Canada. J Clin Psychiatry. 2014; 75(2): 154-161.
3. Roerig JL, Steffen KJ,Mitchell JE. Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs. 2011; 25(12): 1035-1059.
4. Ebdrup BH, Knop FK, Madsen A, et al. Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. J Clin Psychiatry. 2014; 75(9): E899-e905.
5. Hahn MK,Wolever TM, Arenovich T, et al. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol. 2013; 33(6): 740-746.
6. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28(3): 519-526.
7. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007; 104(9): 3456-3459.
8. Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav. 2011; 104(4): 590-598.
9. HeM, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs. 2013; 27(6): 423-434.
10. Rasmussen H, Ebdrup BH, Oranje B, Pinborg LH, Knudsen GM, Glenthøj B. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients. Int J Neuropsychopharmacol. 2014; 17(11): 1729-1736.
11. Kahn RS, FleischhackerWW, Boter H, et al; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 2008; 371(9618): 1085-1097.
12. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD000284.
13. Thornley S, Russell B, Kydd R. Carbohydrate reward and psychosis: An explanation for neuroleptic induced weight gain and path to improved mental health? Curr Neuropharmacol. 2011; 9(2): 370-375.
14. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatmentsmeta-analysis. Lancet. 2013; 382(9896): 951-962.
15. Stice E, Spoor S, Ng J, Zald DH. Relation of obesity to consummatory and anticipatory food reward. Physiol Behav. 2009; 97(5): 551-560.
16. Stice E, Yokum S, Bohon C, Marti N, Smolen A. Reward circuitry responsivity to food predicts future increases in body mass: Moderating effects of DRD2 and DRD4. Neuroimage. 2010; 50(4): 1618-1625.
17. Stice E, Yokum S, Zald D, Dagher A. Dopamine-based reward circuitry responsivity, genetics, and overeating. Curr Top Behav Neurosci. 2011; 6: 81-93.
18. Stice E, Figlewicz DP, Gosnell BA, Levine AS, PrattWE. The contribution of brain reward circuits to the obesity epidemic. Neurosci Biobehav Rev. 2013; 37(9, pt A): 2047-2058.
19. Mariotti KC, Rossato LG, Fröehlich PE, Limberger RP. Amphetamine-type medicines: A review of pharmacokinetics, pharmacodynamics, and toxicological aspects. Curr Clin Pharmacol. 2013; 8(4): 350-357.
20. Bray GA. Use and abuse of appetitesuppressant drugs in the treatment of obesity. Ann Intern Med. 1993; 119(7, pt 2): 707-713.
21. Lee MD, Clifton PG. Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav. 2002; 71(1-2): 147-154.
22. Blum K, Liu Y, Shriner R, GoldMS. Reward circuitry dopaminergic activation regulates food and drug craving behavior. Curr Pharm Des. 2011; 17 (12): 1158-1167.
23. Blum K, Thanos PK, GoldMS. Dopamine and glucose, obesity, and reward deficiency syndrome. Front Psychol. 2014; 5: 919.
24. Stice E, Yokum S, Blum K, Bohon C.Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 2010; 30(39): 13105-13109.
25. Stice E, Spoor S, Bohon C, Veldhuizen MG, Small DM. Relation of reward from food intake and anticipated food intake to obesity: A functional magnetic resonance imaging study. J Abnorm Psychol. 2008; 117(4): 924-935.
26. Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008; 322(5900): 449-452.
27. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006; 29(2): 409-416.
28. Schlagenhauf F, Sterzer P, Schmack K, et al. Reward feedback alterations in unmedicated schizophrenia patients: Relevance for delusions. Biol Psychiatry. 2009; 65(12): 1032-1039.
29. Nielsen MO, Rostrup E,Wulff S, et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry. 2012; 71(10): 898-905.
30. Esslinger C, Englisch S, Inta D, et al. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res. 2012; 140(1-3): 114-121.
31. SimonV, vanWinkel R, DeHert M. Areweight gain and metabolic side effects of atypical antipsychotics dose dependent? a literature review. J Clin Psychiatry. 2009; 70(7): 1041-1050.
32. Mathews J, Newcomer JW, Mathews JR, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry. 2012; 69(12): 1226-1237.
33. Grimm O, Vollstädt-Klein S, Krebs L, Zink M, Smolka MN. Reduced striatal activation during reward anticipation due to appetite-provoking cues in chronic schizophrenia: A fMRI study. Schizophr Res. 2012; 134(2-3): 151-157.
34. ClinicalTrials.gov. Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS). NCT01154829. https://clinicaltrials.gov/ct2/show/NCT01154829. Accessed November 25, 2015.
35. Wing JK, Babor T, Brugha T, et al. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990; 47(6): 589-593.
36. World Medical Association.World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191-2194. doi: 10.1001/jama.2013.281053.
37. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
38. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976; 33(6): 766-771.
39. Crespo-Facorro B, Roiz-Santiáñez R, Pelayo-Terán JM, et al. Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. Schizophr Res. 2007; 91(1-3): 87-96.
40. Nielsen MO, Rostrup E,Wulff S, et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry. 2012; 69(12): 1195-1204.
41. Wulff S, Pinborg LH, Svarer C, et al. Striatal D(2/3) binding potential values in drug-naïve first-episode schizophrenia patients correlate with treatment outcome. Schizophr Bull. 2015; 41(5): 1143-1152.
42. Ebdrup BH, Raghava JM, Nielsen MO, Rostrup E, Glenthøj B. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. J Psychiatry Neurosci. 2015; 41(1): 150030.
43. Düring S, Glenthøj BY, Andersen GS, Oranje B. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology. 2014; 39(13): 3000-3008.
44. Zink CF, Pagnoni G, Martin ME, DhamalaM, Berns GS. Human striatal response to salient nonrewarding stimuli. J Neurosci. 2003; 23(22): 8092-8097.
45. Schlagenhauf F, Juckel G, Koslowski M, et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl). 2008; 196(4): 673-684.
46. Rothemund Y, Preuschhof C, Bohner G, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007; 37(2): 410-421.
47. Murdaugh DL, Cox JE, Cook EW III,Weller RE. fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program. Neuroimage. 2012; 59(3): 2709-2721.
48. Haber SN, Knutson B. The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology. 2010; 35(1): 4-26.
49. Guo J, Simmons WK, Herscovitch P, Martin A, Hall KD. Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry. 2014; 19(10): 1078-1084.
50. Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011; 128(1-3): 166-170.
51. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001; 62(4): 231-238.
52. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: A differential association. J Clin Psychopharmacol. 2002; 22(3): 244-251.
53. Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD.Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol. 2005; 19(6) (suppl): 110-117.
54. Simon JJ, Skunde M,Wu M, et al. Neural dissociation of food and money related reward processing using an abstract incentive delay task. Soc Cogn Affect Neurosci. 2015; 10(8): 1113-1120.
55. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160(2): 284-289.